Addictions
Province provides 3.4 million to transition Red Deer away from drug consumption site
In Red Deer, Alberta’s government is increasing access to recovery-oriented care by launching several new initiatives within the community.
Alberta’s government has built a system of care based on the belief that recovery is possible for those suffering from the disease of addiction. The focus has been on reducing barriers to recovery by increasing capacity and ensuring that no one is forced to pay for life-saving addiction treatment. Since 2019, the province has added more than 10,000 new addiction treatment spaces. It has also removed financial barriers and pioneered a program for immediate, same-day access to life-saving evidence-based treatment medication.
Red Deer is home to Alberta’s first of 11 recovery communities being built by the province. This facility opened its doors in May 2023 and has become a beacon of hope for those suffering from addiction, along with their families. Red Deer was also the first in Alberta to open a Therapeutic Living Unit within its correctional center. This means the recovery community model of treatment has been adopted in corrections, lowering the chances of reoffending and breaking the cycle of addiction and crime in individuals’ lives. Access to opioid agonist therapy has been expanded to police cells through the Virtual Opioid Dependency Program and can also be administered by specialized paramedics with support from the province.
Earlier this year, Red Deer city council put forward and passed a motion requesting a transition of the drug consumption site to instead implement options focused on health, wellness and recovery.
In response to this request, Alberta’s government has committed $3.4 million to provide the following:
- A Mobile Rapid Access Addiction Medicine clinic operated by Recovery Alberta, located in the homeless shelter parking lot. This will offer screening, diagnosis and referral to services; access to the Virtual Opioid Dependency Program; and education, naloxone kits and needle exchange.
- A Dynamic Overdose Response Team of paramedics and licensed practical nurses to monitor a designated area of the Safe Harbour shelter facility, as well as the surrounding block.
- Recovery coaches in and around the homeless shelter to provide outreach services and help guide individuals along the path of recovery.
- Enhancements to medically supported detox capacity in partnership with Safe Harbour that will help more people safely withdraw from substances so they can continue their pursuit of recovery.
In addition, Alberta’s government recently provided more than $1.2 million over the next two years to the Red Deer Dream Centre to support 20 additional publicly funded addiction treatment beds.
“Our government will always listen to and take seriously the feedback we receive from elected local leaders. This is a well-thought-out plan that aligns with Red Deer’s needs and requests, which is why the province is making these changes and increasing support for the community. We remain committed to protecting the health and well-being of Albertans while actively supporting connections to treatment and recovery.”
“Our council is pleased to see this new path forward for recovery-oriented services in Red Deer. At the heart of our council’s and community’s efforts is the belief that recovery is possible for everyone, especially the most vulnerable. This is a complex challenge and only by working with all our partners at the province, agencies, businesses, faith communities and all Red Deerians will we create a safe, healthy and prosperous community. We look forward to close collaboration with the province as these changes are made.”
Alberta’s government is working closely with the City of Red Deer, Safe Harbour Society, Recovery Alberta and others to implement these supports starting this fall.
Since October 2018, the Red Deer drug consumption site has been operating at a temporary site within an ATCO trailer in the parking lot next to Safe Harbour Society’s detox building. As requested by the city council, the drug consumption site will be transitioned out of Red Deer once all other services are operational, which is anticipated to be in spring 2025. The program expansion for recovery services represents a net increase in programming and staffing.
“We look forward to bringing a new service to Red Deer with the opening of a Mobile Rapid Access Addiction Medicine clinic. With this and the new outreach services being put in place, Recovery Alberta will provide opportunities for those facing addiction and mental health issues to access support on an ongoing basis.”
“I am pleased to see that Alberta’s government is working collaboratively with our local government and service providers. This plan ensures we prioritize Red Deer’s needs while also supporting individuals in their pursuit of recovery.”
“Red Deer is a beautiful community with wonderful families and individuals. Transitioning the drug site out of Red Deer and focusing on recovery is the right thing to do. Thank you to the Government of Alberta and Red Deer City Council for leading, listening and doing what is right.”
“We are pleased to partner with Alberta’s government, Recovery Alberta and the City of Red Deer to increase access to addiction and detox services for those accessing supports at Safe Harbour. This partnership profoundly enhances our capacity to meet the needs of community members challenged by addiction and to support them in their recovery journey.”
Alberta is making record investments and removing barriers to recovery-oriented supports for all Albertans, regardless of where they live or their financial situation. This includes the addition of more than 10,000 new publicly funded addiction treatment spaces, expanded access to the Virtual Opioid Dependency Program—which provides same-day access to life-saving treatment medication—the removal of daily user fees for publicly funded live-in treatment, and the construction of 11 world-class recovery communities.
Quick facts
- Albertans struggling with opioid addiction can contact the Virtual Opioid Dependency Program (VODP) by calling 1-844-383-7688, seven days a week, from 6 a.m. to midnight. VODP provides same-day access to addiction medicine specialists. There is no wait list.
Related information
Related news
Addictions
The War on Commonsense Nicotine Regulation
From the Brownstone Institute
Cigarettes kill nearly half a million Americans each year. Everyone knows it, including the Food and Drug Administration. Yet while the most lethal nicotine product remains on sale in every gas station, the FDA continues to block or delay far safer alternatives.
Nicotine pouches—small, smokeless packets tucked under the lip—deliver nicotine without burning tobacco. They eliminate the tar, carbon monoxide, and carcinogens that make cigarettes so deadly. The logic of harm reduction couldn’t be clearer: if smokers can get nicotine without smoke, millions of lives could be saved.
Sweden has already proven the point. Through widespread use of snus and nicotine pouches, the country has cut daily smoking to about 5 percent, the lowest rate in Europe. Lung-cancer deaths are less than half the continental average. This “Swedish Experience” shows that when adults are given safer options, they switch voluntarily—no prohibition required.
In the United States, however, the FDA’s tobacco division has turned this logic on its head. Since Congress gave it sweeping authority in 2009, the agency has demanded that every new product undergo a Premarket Tobacco Product Application, or PMTA, proving it is “appropriate for the protection of public health.” That sounds reasonable until you see how the process works.
Manufacturers must spend millions on speculative modeling about how their products might affect every segment of society—smokers, nonsmokers, youth, and future generations—before they can even reach the market. Unsurprisingly, almost all PMTAs have been denied or shelved. Reduced-risk products sit in limbo while Marlboros and Newports remain untouched.
Only this January did the agency relent slightly, authorizing 20 ZYN nicotine-pouch products made by Swedish Match, now owned by Philip Morris. The FDA admitted the obvious: “The data show that these specific products are appropriate for the protection of public health.” The toxic-chemical levels were far lower than in cigarettes, and adult smokers were more likely to switch than teens were to start.
The decision should have been a turning point. Instead, it exposed the double standard. Other pouch makers—especially smaller firms from Sweden and the US, such as NOAT—remain locked out of the legal market even when their products meet the same technical standards.
The FDA’s inaction has created a black market dominated by unregulated imports, many from China. According to my own research, roughly 85 percent of pouches now sold in convenience stores are technically illegal.
The agency claims that this heavy-handed approach protects kids. But youth pouch use in the US remains very low—about 1.5 percent of high-school students according to the latest National Youth Tobacco Survey—while nearly 30 million American adults still smoke. Denying safer products to millions of addicted adults because a tiny fraction of teens might experiment is the opposite of public-health logic.
There’s a better path. The FDA should base its decisions on science, not fear. If a product dramatically reduces exposure to harmful chemicals, meets strict packaging and marketing standards, and enforces Tobacco 21 age verification, it should be allowed on the market. Population-level effects can be monitored afterward through real-world data on switching and youth use. That’s how drug and vaccine regulation already works.
Sweden’s evidence shows the results of a pragmatic approach: a near-smoke-free society achieved through consumer choice, not coercion. The FDA’s own approval of ZYN proves that such products can meet its legal standard for protecting public health. The next step is consistency—apply the same rules to everyone.
Combustion, not nicotine, is the killer. Until the FDA acts on that simple truth, it will keep protecting the cigarette industry it was supposed to regulate.
Addictions
The Shaky Science Behind Harm Reduction and Pediatric Gender Medicine

By Adam Zivo
Both are shaped by radical LGBTQ activism and questionable evidence.
Over the past decade, North America embraced two disastrous public health movements: pediatric gender medicine and “harm reduction” for drug use. Though seemingly unrelated, these movements are actually ideological siblings. Both were profoundly shaped by extremist LGBTQ activism, and both have produced grievous harms by prioritizing ideology over high-quality scientific evidence.
While harm reductionists are known today for championing interventions that supposedly minimize the negative effects of drug consumption, their movement has always been connected to radical “queer” activism. This alliance began during the 1980s AIDS crisis, when some LGBTQ activists, hoping to reduce HIV infections, partnered with addicts and drug-reform advocates to run underground needle exchanges.
The Bureau is a reader-supported publication.
To receive new posts and support my work, consider becoming a free or paid subscriber.
In the early 2000s, after the North American AIDS epidemic was brought under control, many HIV organizations maintained their relevance (and funding) by pivoting to addiction issues. Despite having no background in addiction medicine, their experience with drug users in the context of infectious diseases helped them position themselves as domain experts.
These organizations tended to conceptualize addiction as an incurable infection—akin to AIDS or Hepatitis C—and as a permanent disability. They were heavily staffed by progressives who, influenced by radical theory, saw addicts as a persecuted minority group. According to them, drug use itself was not the real problem—only society’s “moralizing” norms.
These factors drove many HIV organizations to lobby aggressively for harm reduction at the expense of recovery-oriented care. Their efforts proved highly successful in Canada, where I am based, as HIV researchers were a driving force behind the implementation of supervised consumption sites and “safer supply” (free, government-supplied recreational drugs for addicts).
From the 2010s onward, the association between harm reductionism and queer radicalism only strengthened, thanks to the popularization of “intersectional” social justice activism that emphasized overlapping forms of societal oppression. Progressive advocates demanded that “marginalized” groups, including drug addicts and the LGBTQ community, show enthusiastic solidarity with one another.
These two activist camps sometimes worked on the same issues. For example, the gay community is struggling with a silent epidemic of “chemsex” (a dangerous combination of drugs and anonymous sex), which harm reductionists and queer theorists collaboratively whitewash as a “life-affirming cultural practice” that fosters “belonging.”
For the most part, though, the alliance has been characterized by shared tones and tactics—and bad epistemology. Both groups deploy politicized, low-quality research produced by ideologically driven activist-researchers. The “evidence-base” for pediatric gender medicine, for example, consists of a large number of methodologically weak studies. These often use small, non-representative samples to justify specious claims about positive outcomes. Similarly, harm reduction researchers regularly conduct semi-structured interviews with small groups of drug users. Ignoring obvious limitations, they treat this testimony as objective evidence that pro-drug policies work or are desirable.
Gender clinicians and harm reductionists are also averse to politically inconvenient data. Gender clinicians have failed to track long-term patient outcomes for medically transitioned children. In some cases, they have shunned detransitioners and excluded them from their research. Harm reductionists have conspicuously ignored the input of former addicts, who generally oppose laissez-faire drug policies, and of non-addict community members who live near harm-reduction sites.
Both fields have inflated the benefits of their interventions while concealing grievous harms. Many vulnerable children, whose gender dysphoria otherwise might have resolved naturally, were chemically castrated and given unnecessary surgeries. In parallel, supervised consumption sites and “safer supply” entrenched addiction, normalized public drug use, flooded communities with opioids, and worsened public disorder—all without saving lives.
In both domains, some experts warned about poor research practices and unmeasured harms but were silenced by activists and ideologically captured institutions. In 2015, one of Canada’s leading sexologists, Kenneth Zucker, was fired from the gender clinic he had led for decades because he opposed automatically affirming young trans-identifying patients. Analogously, dozens of Canadian health-care professionals have told me that they feared publicly criticizing aspects of the harm-reduction movement. They thought doing so could invite activist harassment while jeopardizing their jobs and grants.
By bullying critics into silence, radical activists manufactured false consensus around their projects. The harm reductionists insist, against the evidence, that safer supply saves lives. Their idea of “evidence-based policymaking” amounts to giving addicts whatever they ask for. “The science is settled!” shout the supporters of pediatric gender medicine, though several systematic reviews proved it was not.
Both movements have faced a backlash in recent years. Jurisdictions throughout the world are, thankfully, curtailing irreversible medical procedures for gender-confused youth and shifting toward a psychotherapy-based “wait and see” approach. Drug decriminalization and safer supply are mostly dead in North America and have been increasingly disavowed by once-supportive political leaders.
Harm reductionists and queer activists are trying to salvage their broken experiments, occasionally by drawing explicit parallels between their twin movements. A 2025 paper published in the International Journal of Drug Policy, for example, asserts that “efforts to control, repress, and punish drug use and queer and trans existence are rising as right-wing extremism becomes increasingly mainstream.” As such, there is an urgent need to “cultivate shared solidarity and action . . . whether by attending protests, contacting elected officials, or vocally defending these groups in hostile spaces.”
How should critics respond? They should agree with their opponents that these two radical movements are linked—and emphasize that this is, in fact, a bad thing. Large swathes of the public understand that chemically and surgically altering vulnerable children is harmful, and that addicts shouldn’t be allowed to commandeer public spaces. Helping more people grasp why these phenomena arose concurrently could help consolidate public support for reform and facilitate a return to more restrained policies.
Adam Zivo is director of the Canadian Centre for Responsible Drug Policy.
For the full experience, please upgrade your subscription and support a public interest startup.
We break international stories and this requires elite expertise, time and legal costs.
-
Agriculture2 days agoDanish Cows Collapsing Under Mandatory Methane-Reducing Additive
-
Alberta2 days agoAlberta government’s plan will improve access to MRIs and CT scans
-
Business2 days agoNo Jobs Clause: Liberals Under Fire Over Stellantis Deal in Fiery Committee Showdown
-
Economy2 days agoWelcome to the Energy Humanist Club! Bill Gates breaks the moral monopoly against fossil fuels
-
Business1 day agoBudget 2025 continues to balloon spending and debt
-
Censorship Industrial Complex1 day agoHow the UK and Canada Are Leading the West’s Descent into Digital Authoritarianism
-
Business1 day agoCapital Flight Signals No Confidence In Carney’s Agenda
-
Business1 day agoFederal budget: Carney government posts largest deficit in Canadian history outside pandemic





